These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 16941234)

  • 1. Assessment of dosing impact on intra-individual variability in estimation of parameters for basic indirect response models.
    Krzyzanski W; Dmochowski J; Matsushima N; Jusko WJ
    J Pharmacokinet Pharmacodyn; 2006 Oct; 33(5):635-55. PubMed ID: 16941234
    [TBL] [Abstract][Full Text] [Related]  

  • 2. D-optimal designs for parameter estimation for indirect pharmacodynamic response models.
    Khinkis LA; Krzyzanski W; Jusko WJ; Greco WR
    J Pharmacokinet Pharmacodyn; 2009 Dec; 36(6):523-39. PubMed ID: 19904585
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Methods of utilizing baseline values for indirect response models.
    Woo S; Pawaskar D; Jusko WJ
    J Pharmacokinet Pharmacodyn; 2009 Oct; 36(5):381-405. PubMed ID: 19697107
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A pharmacometric case study regarding the sensitivity of structural model parameter estimation to error in patient reported dosing times.
    Knights J; Rohatagi S
    J Pharmacokinet Pharmacodyn; 2015 Dec; 42(6):627-37. PubMed ID: 26209956
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of dose selection on parameter estimation using a rapid binding approximation model of target-mediated drug disposition.
    Marathe A; Van Wart S; Mager DE
    J Pharmacokinet Pharmacodyn; 2011 Apr; 38(2):223-35. PubMed ID: 21165681
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacodynamic parameter estimation: population size versus number of samples.
    Girgis S; Pai SM; Girgis IG; Batra VK
    AAPS J; 2005 Oct; 7(2):46. PubMed ID: 16353905
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An innovative phase I population pharmacokinetic approach to investigate the pharmacokinetics of an intranasal fentanyl spray in healthy subjects.
    Plock N; Facius A; Hartmann L; Baumann S; Nave R
    Int J Clin Pharmacol Ther; 2013 Jun; 51(6):495-508. PubMed ID: 23611571
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A placebo- and midazolam-controlled phase I single ascending-dose study evaluating the safety, pharmacokinetics, and pharmacodynamics of remimazolam (CNS 7056): Part II. Population pharmacokinetic and pharmacodynamic modeling and simulation.
    Wiltshire HR; Kilpatrick GJ; Tilbrook GS; Borkett KM
    Anesth Analg; 2012 Aug; 115(2):284-96. PubMed ID: 22253270
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Some considerations on the design of population pharmacokinetic studies.
    Duffull S; Waterhouse T; Eccleston J
    J Pharmacokinet Pharmacodyn; 2005 Aug; 32(3-4):441-57. PubMed ID: 16284917
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Designs for population pharmacodynamics: value of pharmacokinetic data and population analysis.
    Hashimoto Y; Sheiner LB
    J Pharmacokinet Biopharm; 1991 Jun; 19(3):333-53. PubMed ID: 1875286
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Partial derivative-based sensitivity analysis of models describing target-mediated drug disposition.
    Abraham AK; Krzyzanski W; Mager DE
    AAPS J; 2007 Jun; 9(2):E181-9. PubMed ID: 17614360
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bioavailability estimation by semisimultaneous drug administration: a Monte Carlo simulation study.
    Karlsson MO; Bredberg U
    J Pharmacokinet Biopharm; 1990 Apr; 18(2):103-20. PubMed ID: 2348378
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Simultaneous optimal experimental design on dose and sample times.
    Nyberg J; Karlsson MO; Hooker AC
    J Pharmacokinet Pharmacodyn; 2009 Apr; 36(2):125-45. PubMed ID: 19319484
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Simultaneous vs. sequential analysis for population PK/PD data I: best-case performance.
    Zhang L; Beal SL; Sheiner LB
    J Pharmacokinet Pharmacodyn; 2003 Dec; 30(6):387-404. PubMed ID: 15000421
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessment of basic indirect pharmacodynamic response models with physiological limits.
    Yao Z; Krzyzanski W; Jusko WJ
    J Pharmacokinet Pharmacodyn; 2006 Apr; 33(2):167-93. PubMed ID: 16547797
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetic and pharmacodynamic modeling of recombinant human erythropoietin after single and multiple doses in healthy volunteers.
    Ramakrishnan R; Cheung WK; Wacholtz MC; Minton N; Jusko WJ
    J Clin Pharmacol; 2004 Sep; 44(9):991-1002. PubMed ID: 15317827
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of dosage regimen in controlling indirect pharmacodynamic responses.
    Gobburu JV; Jusko WJ
    Adv Drug Deliv Rev; 2001 Mar; 46(1-3):45-57. PubMed ID: 11259832
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Optimal experimental design for assessment of enzyme kinetics in a drug discovery screening environment.
    Sjögren E; Nyberg J; Magnusson MO; Lennernäs H; Hooker A; Bredberg U
    Drug Metab Dispos; 2011 May; 39(5):858-63. PubMed ID: 21289074
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of ED, EID, and API criteria for the robust optimization of sampling times in pharmacokinetics.
    Tod M; Rocchisani JM
    J Pharmacokinet Biopharm; 1997 Aug; 25(4):515-37. PubMed ID: 9561492
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Simulation studies of errors of parameter estimates in pharmacokinetics.
    Betzien G; Kaufmann B; Schneider B; Ritschel WA
    Arzneimittelforschung; 1985; 35(1):7-14. PubMed ID: 3838673
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.